Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicentre, phase II, open label randomised clinical trial to assess the bleeding profile, tolerability and safety associated with the use of three prolonged release formulations containing a combination of dienogest and ethinyl estradiol versus a flexible regimen contraceptive containing drospirenone 3 mg and ethinyl estradiol 20 µg.

Trial Profile

Multicentre, phase II, open label randomised clinical trial to assess the bleeding profile, tolerability and safety associated with the use of three prolonged release formulations containing a combination of dienogest and ethinyl estradiol versus a flexible regimen contraceptive containing drospirenone 3 mg and ethinyl estradiol 20 µg.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs Ethinylestradiol/dienogest (Primary) ; Drospirenone
  • Indications Pregnancy
  • Focus Therapeutic Use
  • Sponsors Exeltis
  • Most Recent Events

    • 20 Oct 2018 This trial has been completed in Lithuania (end date: 2018-09-24)
    • 07 Dec 2017 Planned number of patients changed from 350 to 400.
    • 20 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top